natgillin/translations-raw huggingface dataset:
De hyppigste bivirkninger ved Rizmoic hos patienter uden kræft (som kan forekomme hos op til 1 ud af 10 personer) er mavesmerter, diarré, kvalme og opkastning.
The most common side effects with Rizmoic in patients without cancer (which may affect up to 1 in 10 people) are abdominal pain (belly ache), diarrhoea, nausea and vomiting.
Hos kræftpatienter var de hyppigste bivirkninger diarré (som optræder hos mere end 1 ud af 10 personer) og mavesmerter (som optræder hos op til 1 ud af 10 personer).
In patients with cancer, the most common side effects were diarrhoea (seen in more than 1 in 10 people) and abdominal pain (seen in up to 1 in 10 people).
I to af studierne, der omfattede 1.095 patienter, som tog opioider for kroniske (langvarige) smerter forårsaget af en anden sygdom end kræft, opnåede 50 % af de patienter, der tog Rizmoic i 12 uger, det ønskede resultat sammenlignet med 34 % af de patienter, der tog placebo.
In two of the studies, involving 1095 patients taking opioids for chronic (long-term) pain caused by a condition other than cancer, 50% of patients taking Rizmoic for 12 weeks achieved the desired outcome, compared with 34% of patients taking placebo.
Hvilke risici er der forbundet med Rizmoic?
What are the risks associated with Rizmoic?
Det er påvist, at Rizmoic forbedrer afføringen hos patienter, som tager smertestillende opioide lægemidler for langvarige smerter (herunder kræftsmerter).
Rizmoic has been shown to improve bowel movement in patients taking opioids pain medicines for long-term pain (including cancer pain).
Rizmoic er et lægemiddel til behandling af forstoppelse forårsaget af smertestillende opioide lægemidler hos patienter, som tidligere er blevet behandlet med et laksativ (afføringsmiddel).
Rizmoic is a medicine for treating constipation caused by opioid pain relief medicines in patients who have previously been treated with a laxative (a medicine that triggers bowel movements).
Studierne har vist, at Rizmoic effektivt forbedrer afføringen hos patienter, der tager afføringsmidler eller tidligere har taget afføringsmidler.
Studies have shown that Rizmoic is effective at improving bowel movement in patients who are currently taking laxatives or had taken laxatives in the past.
Der er anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Rizmoic.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rizmoic have been included in the summary of product characteristics and the package leaflet.
Hvordan anvendes Rizmoic?
How is Rizmoic used?
Hvilke fordele viser studierne, at der er ved Rizmoic?
What benefits of Rizmoic have been shown in studies?
Hvordan virker Rizmoic?
How does Rizmoic work?
Styrke Lægemiddelform Administration Emballage Indhold
Strength Pharmaceutical Form Route of Administration
tmax er mellem 3 og 8 timer.
Tmax is between 3 and 8 hours.
• De må ikke tage en dobbeltdosis som erstatning for den glemte dosis.
● Do not take a double dose to make up for a forgotten dose.
7 dage.
for 7 days.
Fordelingsvolumen er ca. 10 l/kg.
The volume of distribution is around 10 l/kg.
De kan opleve forøgede symptomer, som beskrevet i pkt.
You may experience increased symptoms as described in section 4.
• andre NMDA-antagonister bør undgås.
● other NMDA-antagonists at the same time should be avoided.
Én gang dagligt
Once daily
• cimetidin, ranitidin, procainamid, quinidin, quinin, nikotin
● cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine
20 dage, mere end 99% blev udskilt via nyrerne.
20 days, more than 99% being excreted renally.
Bivirkningerne er opdelt efter organklassesystem med følgende betegnelser: Meget almindelig (1/10), almindelig (1/100 til <1/10), ikke almindelig (1/1.000 til <1/100), sjælden (1/10.000 til <1/1.000), meget sjælden (<1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
• dantrolen, baklofen
● dantrolene, baclofen
• hydrochlorothiazid (eller en hvilken som helst kombination med hydrochlorothiazid)
● hydrochlorothiazide (or any combination with hydrochlorothiazide)
Da virkningerne hverken er observeret i langtidsstutudier med gnavere eller med ikke-gnavere, er den kliniske relevans af disse observationer ukendt.
As the effects have neither been observed in long term studies in rodents nor in non-rodents, the clinical relevance of these findings is unknown.
Børn og unge Memantine ratiopharm anbefales ikke til børn og unge under 18 år.
Children and adolescents Memantine ratiopharm is not recommended for children and adolescents under the age of 18 years.
• Generelt burde indtagelse af for meget Memantine ratiopharm ikke være skadeligt for Dem.
● In general, taking too much Memantine ratiopharm should not result in any harm to you.
Talcum (E 553b)
Talc (E 553b)
• Hvis De har glemt at tage Deres dosis af Memantine ratiopharm, skal De vente og tage Deres næste dosis på det sædvanlige tidspunkt.
● If you find you have forgotten to take your dose of Memantine ratiopharm, wait and take your next dose at the usual time.
Det er ukendt, om memantin udskilles i human brystmælk, men i betragtning af stoffets lipofilicitet forventes dette at være tilfældet.
It is not known whether memantine is excreted in human breast milk but, taking into consideration the lipophilicity of the substance, this probably occurs.
Slabinská 30, 03680 Martin Slovakiet
Slabinská 30, 03680 Martin Slovakia
SL-03680 Martin Slovakiet
SL-03680 Martin Slovakia
I særdeleshed kan Memantine ratiopharm ændre virkningen af følgende lægemidler, og lægen kan derfor være nødt til at ændre doseringen:
In particular, Memantine ratiopharm may change the effects of the following medicines and their dose may need to be adjusted by your doctor:
• amantadin, ketamin, dextromethorfan
● amantadine, ketamine, dextromethorphan
Polysorbat 80 (E 433)
Polysorbate 80 (E 433)
• amantadin (til behandling af Parkinsons sygdom)
● amantadine (for the treatment of Parkinson's disease),
I disse situationer bør behandlingen overvåges nøje, og den kliniske gavn af Memantine ratiopharm skal regelmæssigt vurderes af Deres læge.
In these situations the treatment should be carefully supervised, and the clinical benefit of Memantine ratiopharm reassessed by your doctor on a regular basis.
• dopaminerge agonister (stoffer såsom L-dopa, bromokriptin)
● dopaminergic agonists (substances such as L-dopa, bromocriptine)
Hvis De har nedsat nyrefunktion (nyreproblemer), bør Deres læge nøje overvåge Deres nyrefunktion og om nødvendigt tilpasse memantin-dosen derefter.
If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly.
Memantine ratiopharm gives oralt én gang om dagen og bør indtages på samme tidspunkt hver dag.
Memantine ratiopharm should be administered orally once a day and should be taken at the same time every day.
Startpakken til behandling med Memantine ratiopharm må kun anvendes i begyndelsen af behandlingen med Memantine ratiopharm.
The Memantine ratiopharm treatment initiation pack is only to be used for the beginning of the treatment with Memantine ratiopharm.
Tag én tablet én gang dagligt.
Take one tablet once a day.
Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data): • Betændelse i bugspytkirtlen, leverbetændelse (hepatitis) og psykotiske reaktioner.
Not known (frequency cannot be estimated from the available data): ● Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions
- Efter markedsføringen er der rapporteret enkeltstående tilfælde af stigninger i INR (International normalized ratio) hos patienter i samtidig behandling med warfarin.
- In post-marketing experience, isolated cases with international normalized ratio (INR) increases have been reported in patients concomitantly treated with warfarin.
Memantine ratiopharm hører til en gruppe af lægemidler kaldet NMDA-receptor-antagonister.
Memantine ratiopharm belongs to a group of medicines called NMDA-receptor antagonists.
Der er ingen eller utilstrækkelige data fra anvendelse af memantin til gravide kvinder.
There are no or limited amount of data from the use of memantine in pregnant women.
- Virkemåden antyder, at effekten af L-dopa, dopaminerge agonister og antikolinergika kan forstærkes ved samtidig behandling med NMDA-antagonister såsom memantin.
- The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Farmakoterapeutisk klassifikation: Psychoanaleptica.
Pharmacotherapeutic group: Psychoanaleptics.
Samtidig brug af N-metyl-D-aspartat(NMDA)-antagonister såsom amantadin, ketamin eller dextromethorfan bør undgås.
Concomitant use of N-methyl-D-aspartate (NMDA)-antagonists such as amantadine, ketamine or dextromethorphan should be avoided.
Andre antidemenspræparater, ATC-kode: N06DX01.
Other Anti-dementia drugs, ATC code: N06DX01.
Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisterpakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned.
Do not use this medicine after the expiry date which is stated on the carton and the blister pack after EXP.
Bivirkninger, der forekom oftest og med en højere incidens i gruppen behandlet med memantin end i gruppen behandlet med placebo, var svimmelhed (hhv. 6,3% vs. 5,6%), hovedpine (5,2% vs. 3,9%), forstoppelse (4,6% vs. 2,6%), sløvhed (søvntrang) (3,4% vs. 2,2%) og hypertension (4,1% vs. 2,8%).
The most frequently occurring adverse reactions with a higher incidence in the memantine group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
- Der er mulighed for en reduktion i serumkoncentrationen af hydrochlorothiazid (HCT), når memantin administreres sammen med HCT eller sammen med kombinationspræparater med HCT.
- There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.
Denne øges til en tablet én gang dagligt (1x 10 mg) i den anden uge og til halvanden tablet én gang dagligt i den tredje uge.
This is increased to one tablet once a day (1x 10 mg) in the second week and to one and a half tablets once a day in the third week.
Hovedpine Udmattelse 1 Hallucinationer er hovedsageligt observeret hos patienter med svær Alzheimers sygdom.
Headache Fatigue 1 Hallucinations have mainly been observed in patients with severe Alzheimer's disease.
Den anbefalede vedligeholdelsesdosis er 20 mg én gang dagligt, som nås i begyndelsen af den 4. uge.
The recommended maintenance dose is 20 mg once a day, which is reached at the beginning of the 4th week.
Dyrestudier indikerer en potentiel mulighed for intrauterin væksthæmning ved eksponeringsniveauer, der er identiske med eller lidt højere end human eksponering (se pkt.
Animal studies indicate a potential for reducing intrauterine growth at exposure levels, which are identical or slightly higher than at human exposure (see section 5.3).
• dextromethorfan (anvendes generelt til behandling af hoste) og
● dextromethorphan (generally used to treat cough) and
Når patienterne havde fået konstateret en samtidig forværring i alle tre domæner, viste resultaterne en statistisk signifikant effekt af memantin hvad angår forebyggelse af forværring, eftersom dobbelt så mange placebobehandlede patienter som memantinbehandlede patienter udviste forværring i alle tre domæner (21% vs. 11%, p<0,0001).
When patients were identified with concurrent worsening in all three domains, results showed a statistically significant effect of memantine in preventing worsening, as twice as many placebo-treated patients as memantine-treated patients showed worsening in all three domains (21% vs. 11%, p<0.0001).
• hvis De for nylig har haft blodprop i hjertet (myokardieinfarkt), eller hvis De lider af dårligt hjerte eller ukontrolleret forhøjet blodtryk (hypertension).
● if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).
Disse hændelser er blevet beskrevet hos patienter i behandling med memantin.
These events have been reported in patients treated with memantine.
• hvis De tidligere har haft epileptiske anfald
● if you have a history of epileptic seizures.
Derudover påvirker Memantine ratiopharm i mindre til moderat grad evnen til at føre motorkøretøj og betjene maskiner, hvorfor ambulante patienter skal gøres opmærksom på at være særlig forsigtige.
Furthermore, Memantine ratiopharm has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.
• hvis De er allergisk over for memantinhydrochlorid, jordnødder eller soja eller et af de øvrige indholdsstoffer i Memantine ratiopharm (angivet i punkt 6).
● if you are allergic to memantine hydrochloride, peanut or soya or any of the other ingredients of this medicine (listed in section 6).
Memantine ratiopharm findes i pakninger med 28 (7 + 7 + 7 + 7) filmovertrukne tabletter.
Memantine ratiopharm is available in packs with 28 (7 +7 +7 + 7) film-coated tablets.
Tabletterne med 10 mg og 20 mg kan deles i to lige store doser.
The 10 mg and 20 mg tablet can be divided into equal doses.
Disse forbindelser påvirker det samme receptorsystem som memantin, og der kan derfor forekomme hyppigere og mere udtalte bivirkninger (hovedsageligt i centralnervesystemet (CNS)) (se også pkt.
These compounds act at the same receptor system as memantine, and therefore adverse reactions (mainly central nervous system (CNS)-related) may be more frequent or more pronounced (see also section 4.5).
Humane hovedmetabolitter er N-3,5-dimethyl-gludantan, den isomeriske blanding af 4 - og 6-hydroxy-memantin og 1-nitroso-3,5-dimethyl-adamantan.
Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4-and 6-hydroxymemantine, and 1-nitroso-3,5-dimethyl-adamantane.
Memantine ratiopharm anvendes til behandling af patienter med moderat til svær Alzheimers sygdom.
Memantine ratiopharm is used for the treatment of patients with moderate to severe Alzheimer's disease.
Hver pakning med 28 filmovertrukne tabletter til et 4-ugers behandlingsprogram indeholder: 7 x 5 mg og 7 x 10 mg og 7 x 15 mg og 7 x 20 mg filmovertrukne tabletter
Each pack of 28 film-coated tablets for a 4 week treatment schedule contains: 7 x 5 mg and 7 x 10 mg and 7 x 15 mg and 7 x 20 mg film-coated tablets
Memantine ratiopharm indvirker på disse NMDA-receptorer og forbedrer overførslen af nervesignaler samt hukommelsen.
Memantine ratiopharm acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
• orale antikoagulantia.
● oral anticoagulants
Den maksimale daglige dosis er 20 mg dagligt.
The maximum daily dose is 20 mg per day.
I et studie med peroral indgivelse af 14C-memantin blev gennemsnitligt 84% af dosis udskilt inden for
In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within
Daglige doser på 20 mg giver steady-state-plasmakoncentrationer for memantin på mellem 70 og 150 ng/ml (0,5 - 1 µmol) med store interindividuelle variationer.
Daily doses of 20 mg lead to steady-state plasma concentrations of memantine ranging from 70 to 150 ng/ml (0.5-1 μmol) with large interindividual variations.
Kontakt lægen eller apotekspersonalet, før De tager Memantine ratiopharm:
Talk to your doctor or pharmacist before taking Memantine ratiopharm:
HDPE(højdensitets-polyethylen)-flasker med PP(polypropylen)-låg Pakningsstørrelser på 100 filmovertrukne tabletter.
HDPE (high-density polyethylene) bottles with PP (polypropylene) caps Pack sizes of 100 film-coated tablets.
Meget sjældne (påvirker færre end 1 ud af 10.000 patienter): • Krampeanfald.
Very Rare (affects less than 1 user in 10,000): ● Seizures
Sojalecithin (E 322)
Soya lecithin (E 322)
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis for the Clinician´s interview based impression of change” (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study - activities of daily living (ADCS-ADLsev): p=0,003; Severe impairment battery (SIB): p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer's disease cooperative study - activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Almindelig Almindelig Ikke almindelig Meget sjælden
Common Common Uncommon Very rare
4 “Bivirkninger”.
“Possible side effects”.
Dato for første markedsføringstilladelse: 13 juni 2013 Dato for seneste fornyelse:
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 13 June 2013
Den anbefalede dosis på 20 mg Memantine ratiopharm dagligt opnås ved en gradvis øgning af dosis i løbet af de første tre ugers behandling.
The recommended treatment dose of 20 mg per day is achieved by a gradual increase of the Memantine ratiopharm dose during the first 3 weeks of treatment.
Denne medicin indeholder sojalecithin.
This medicine contains soya lecithin.
Fra og med den fjerde uge er den normale dosis 2 tabletter én gang dagligt (1x 20 mg).
From the fourth week on, the usual dose is two tablets once a day (1x 20 mg).
Samtidig brug af lægemidler ved navn
The use of medicinal products called
EXP Opbevaringstid efter første åbning: 6 måneder.
EXP Shelf life after first opening: 6 months.
Hvis De kommer på hospitalet, skal De sige til lægen, at De får Memantine ratiopharm.
If you go into hospital, let your doctor know that you are taking Memantine ratiopharm.
Den normale startdosis er en halv tablet en gang dagligt (1x 5 mg) i den første uge.
The usual starting dose is half a tablet once a day (1x 5 mg) for the first week.
I tilfælde af overdosering med doser under 140 mg eller ukendt dosis har patienterne haft symptomer, der stammede fra centralnervesystemet (forvirring, døsighed, sløvhed (søvntrang), svimmelhed, agitation, aggression, hallucinationer og gangforstyrrelser) og/eller fra mave-tarm-kanalen (opkastning og diarré).
In the overdose cases below 140 mg or unknown dose the patients revealed symptoms from central nervous system (confusion, drowsiness, somnolence, vertigo, agitation, aggression, hallucination, and gait disturbance) and/or of gastrointestinal origin (vomiting and diarrhoea).
Almindelige (påvirker 1-10 ud af 100 patienter):
Common (affects 1 to 10 users in 100):
Behandlingen startes med 5 mg én gang dagligt.
At the beginning of treatment you will start by using 5 mg once a day.
Patienten bør tage to 10 mg filmovertrukne tabletter (20 mg) eller en 20 mg filmovertrukket tablet dagligt.
The patient should take two 10 mg film-coated tablets (20 mg) or one 20 mg film-coated tablet per day.
Tag ikke Memantine ratiopharm:
Do not take Memantine ratiopharm:
Svimmelhed Balanceforstyrrelser Unormal gang Krampeanfald
Dizziness Balance disorders Gait abnormal Seizures
In vitro er der ikke fundet nogen cytokrom P 450-metabolisme.
No cytochrome P 450 catalysed metabolism has been detected in vitro.
Ved en dosis af memantin på 20 mg pr. dag svarer CSF-niveauerne til ki-værdien (ki = hæmningsfaktor) for memantin, som er 0,5 µmol i den humane frontale cortex.
At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Hallucinationer1
Somnolence Confusion Hallucinations1
Hos patienter behandlet med memantin sås statistisk signifikant bedre effekt på de primære effektmål end hos patienter behandlet med placebo: Alzheimer´s disease assessment scale (ADAS-cog) (p=0,003) og CIBIC-plus (p=0,004) i uge 24 (Last observation carried forward (LOCF)).
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer's disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 (last observation carried forward (LOCF)).
Den anbefalede startdosis er 5 mg dagligt med trinvis dosisøgning i de første 4 uger af behandlingen, indtil den anbefalede vedligeholdelsesdosis nås, som følger:
The recommended starting dose is 5 mg per day which is stepwise increased over the first 4 weeks of treatment reaching the recommended maintenance dose as follows:
1. uge (dag 1-7):
Week 1 (day 1-7):
På baggrund af de kliniske studier er den anbefalede dosis til patienter over 65 år 20 mg dagligt (20 mg én gang dagligt) som beskrevet ovenfor.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (20 mg once a day) as described above.
Memantin anbefales ikke til gravide kvinder.
The use of memantine in pregnant women is not recommended.
2. uge (dag 8-14):
Week 2 (day 8-14):
• Hvis De tager en stor overdosis af Memantine ratiopharm, skal De søge læge, da De kan have behov for medicinsk behandling.
● If you take a large overdose of Memantine ratiopharm, contact your doctor or get medical advice,
Efter markedsføringen er disse hændelser rapporteret hos patienter i behandling med memantin.
In postmarketing experience these reactions have been reported in patients treated with memantine.
I studier af toksicitet efter gentagne doser var der modstridende observationer af okulære forandringer hos gnavere og hunde, men ikke hos aber.
Ocular changes were inconsistently observed in repeat dose toxicity studies in rodents and dogs, but not in monkeys.
Kvinder, der tager Memantine ratiopharm, bør ikke amme.
Women taking Memantine ratiopharm should not breast-feed.
• neuroleptika (stoffer, der bruges til behandling af sindslidelser)
● neuroleptics (substances used in the treatment of mental disorders)
For at mindske risikoen for bivirkninger opnås denne dosis gradvist ud fra nedenstående daglige behandlingsforløb.
In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme.
• antikonvulsiva (stoffer, der bruges til at forebygge og afhjælpe krampeanfald)
● anticonvulsants (substances used to prevent and relieve seizures)
Memantine ratiopharm indeholder lactose og sojalecithin Denne medicin indeholder lactose.
Memantine ratiopharm contains lactose and soya lecithin This medicine contains lactose.
Den anbefalede dosis af Memantine ratiopharm til voksne og ældre patienter er 20 mg én gang dagligt.
The recommended dose of Memantine ratiopharm for adults and older patients is 20 mg once a day.
LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) Startpakke til behandling
PHARMACEUTICAL FORM AND CONTENTS Treatment initiation pack
• barbiturater (stoffer, der generelt bruges som sovemidler)
● barbiturates (substances generally used to induce sleep)
3. uge (dag 15-21):
Week 3 (day 15-21):
På baggrund af de kliniske studier er den anbefalede dosis til patienter over 65 år 20 mg dagligt (to 10 mg filmovertrukne tabletter eller en 20 mg filmovertrukket tablet én gang dagligt), som beskrevet ovenfor.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg film-coated tablets or one 20 mg film-coated tablet once a day) as described above.
4. uge (dag 22-28):
Week 4 (day 22-28):
6.5 Emballagetype og pakningsstørrelser PVC/ PVDC-aluminiumsfolie-blisterpakninger Pakningsstørrelser på 28 (7 +7 +7 + 7) filmovertrukne tabletter.
PVC/PVDC-Aluminium foil blister packs Pack sizes of 28 (7 +7 +7 + 7) film-coated tablets.
Memantine ratiopharm bør indtages gennem munden en gang dagligt.
Memantine ratiopharm should be administered orally once a day.